slides · global inventory
All filtered slides
Global slide inventory for the active corpus filters, with each row opening the slide detail view.
Corpus coverage
319,975 slides
319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.
- Total slides
- 319,975
- Described
- 319,974
- Pending
- 1
100%ready for canon
Slide type composition
dynamicclickable
Slide type
Showing 319,974 described slides — 100.0% of 319,975 rendered pages
+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs
Tile area is proportional to slide count. Click a category to open its subtype map.
all document kinds · all orientations
Slide collection
224,161-224,190 of 319,975
25
The slide uses a process flow diagram to illustrate the transition from dose escalation (DL1-DLx) to expansion cohorts for specific indications.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
26
Kymera | Investor Presentation Deck | 46 slidesKymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
27
Data cut-off: 18 October 2023. Includes breakdown by age, sex, ECOG status, prior therapy, and tumor type.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
28
Clinical trial safety data summary.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
29
The table tracks clinical trial outcomes (PR: Partial Response, SD: Stable Disease, PD: Progressive Disease) for a drug candidate.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
30
Includes both tabular summary of dose-level degradation and visual histology/bar chart evidence of tumor reduction.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
31
Includes longitudinal line charts for blood mRNA levels and a bar chart/enrichment plot for tumor response.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
32
The slide uses a split-layout: left side for clinical data results, right side for strategic opportunity/implications.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
33
Kymera | Investor Presentation Deck | 46 slidesKymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
34
Includes a waterfall plot showing p53WT cell dependency on MDM2 and a biological process diagram of the MDM2-p53 feedback loop.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
35
Includes three dose-response curves and a comparative table of clinical stage and potency metrics.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
36
Comparison of protein levels and tumor volume over time across multiple dosing regimens.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
37
The slide uses a standard clinical trial dose-escalation diagram and a demographic table.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
38
The slide uses a biological mechanism diagram on the left and clinical data (table and line chart) on the right to validate the drug's mechanism of action.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
39
The chart is a swimmer plot, a standard tool in oncology clinical trials to visualize duration of response.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
40
Clinical trial safety reporting slide.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
41
The slide uses a split-layout comparing technical mechanism/data (left) with strategic opportunity (right).Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
42
Kymera | Investor Presentation Deck | 46 slidesKymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
43
This is a standard closing slide for an investor presentation.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
44
Kymera | Investor Presentation Deck | 46 slidesKymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
45
The table displays patient counts and percentages for specific adverse events categorized by dose level (DL1-DL5) and overall.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
46
Includes both a summary table of response categories and a swimmer plot for treatment duration.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
01
Lakeland Bancorp | Results Presentation Deck | 16 slidesLakeland Bancorp | Results Presentation Deck | 16 slides · Lakeland Bancorp
Conference presentation Investor relations 1 hit
02
Lakeland Bancorp | Results Presentation Deck | 16 slidesLakeland Bancorp | Results Presentation Deck | 16 slides · Lakeland Bancorp
Conference presentation Investor relations 1 hit
03
Note: Lakeland's fiscal year end is January 31Lakeland Bancorp | Results Presentation Deck | 16 slides · Lakeland Bancorp
Conference presentation Investor relations Beat · Attention1 hit
04
Lakeland Bancorp | Results Presentation Deck | 16 slidesLakeland Bancorp | Results Presentation Deck | 16 slides · Lakeland Bancorp
Conference presentation Investor relations Beat · Attention1 hit
05
Lakeland Bancorp | Results Presentation Deck | 16 slidesLakeland Bancorp | Results Presentation Deck | 16 slides · Lakeland Bancorp
Conference presentation Investor relations Beat · Attention1 hit
06
Lakeland Bancorp | Results Presentation Deck | 16 slidesLakeland Bancorp | Results Presentation Deck | 16 slides · Lakeland Bancorp
Conference presentation Investor relations Beat · NeedLoop · Cost Of Inaction1 hit
07
The slide uses two waterfall-bridge charts to explain the variance in financial performance metrics.Lakeland Bancorp | Results Presentation Deck | 16 slides · Lakeland Bancorp
Conference presentation Investor relations Beat · NeedLoop · Cost Of Inaction1 hit
08
Lakeland Bancorp | Results Presentation Deck | 16 slidesLakeland Bancorp | Results Presentation Deck | 16 slides · Lakeland Bancorp
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit